<DOC>
	<DOCNO>NCT02004223</DOCNO>
	<brief_summary>Current standard treatment prostate cancer involve give patient approximately 40 dos radiotherapy , one dose per day 8 week period . The purpose study assess effect give two separate high dos special type precision radiotherapy prostate 5 week ( instead 8 week ) standard radiotherapy . Hypothesis : It safe give patient extra two dos high-precision radiotherapy prior commence short period standard radiotherapy prostate cancer .</brief_summary>
	<brief_title>Early Investigation High Precision Radiotherapy Prior Commencing Standard Radiotherapy Prostate Cancer</brief_title>
	<detailed_description>Prostate cancer account one third new cancer diagnose men approximately 30 % men External Beam Radiotherapy ( EBRT ) primary local therapy . Local persistence prostate cancer treat radiotherapy under-appreciated . Prostate cancer long natural history consequence local persistence may realize many year . Prostate cancer slow growth potential doubling time range week month ( median 42 day ) lead hypothesis prostate cancer behave like late reacting tissue ( 1 ) . Brenner et al . ( 2 ) use data prostate Low Dose Rate ( LDR ) permanent seed implant EBRT series derive alpha/beta approximately 1.5 . Many group also calculate alpha/beta ratio &lt; 3.0 range ( 3 ) . If alpha/beta ratio prostate cancer lower surround normal tissue ( Brenner et al . estimate alpha/beta rectum 5.0 ) , dose great 2 Gy ( hypofractionation ) afford advantage great sensitivity prostate cancer radiation , compare bladder rectum . This benefit exploit many year High Dose Rate ( HDR ) brachytherapy use Iridium -192 . Typical dos HDR 19Gy two fraction addition 46Gy 23 fraction EBRT ( 4 ) . With reference institutional data HDR brachytherapy calculate dose distribution recently treat patient . Due nature iridium dose distribution , considerable area much high dose deliver ; 200 % dose ( 38Gy ) 12.7 % target volume , 150 % ( 13.75Gy ) 32.6 % target volume 125 % ( 11.9Gy ) 60.1 % target . Despite high dos periphery prostate possible limit dose rectum bladder 1cc &lt; 75 % ( 14.25Gy ) 1cc urethra &lt; 125 % ( 23.75Gy ) ( 4 ) . HDR brachytherapy series report durable long term Biochemical Failure Free Survival ( BFFS ) , good well comparable external beam surgical series ( 5 ) . However despite low toxicity excellent biochemical outcome , HDR brachytherapy utilization Australia low , 300 case total per year . This due logistical difficulty HDR brachytherapy , anaesthetic requirement , nurse care patient discomfort . There five publish study investigate stereotactic boost addition standard fractionation EBRT without use brachytherapy , four report Cyberknife platform ( 6-9 ) one Intensity Modulated Radiotherapy ( IMRT ) ( 10 ) . All series early follow ( FU ) report BFFS 77 % 100 % . The large experience Katz et al . ( 8 ) report 73 patient intermediate ( n= 41 ) high risk ( n=32 ) disease . They treat patient Cyberknife platform deliver 18 21 Gy three fraction addition 45 Gy 25 fraction EBRT . With median follow 33 month , BFFS 89.5 % 77.7 % intermediate high risk patient respectively . A 5 mm expansion prostate Planned Treatment Volume ( PTV ) use except posteriorly , margin 3mm . There 7 % Grade 2 acute genitourinary ( GU ) gastrointestinal ( GI ) toxicity , late Grade 2 estimate three year 5.5 % ( GU ) 8.2 % ( GI ) . Three series use Cyberknife mimic HDR report 2008 2012 ( 6 , 7 , 9 ) . These study use margin 0-2 mm posteriorly 3-5 mm direction report low rate Grade 2 Grade 3 toxicity . Two report specifically attempt reproduce heterogeneity HDR large area PTV receive &gt; 125 % ( 40 % 45 % ) &gt; 150 % ( 5 % 10 % ) prescribe dose . Miralbell et al . ( 10 ) report Linac base IMRT boost 50 patient 2010 . This series use endorectal balloon image guidance , may cause unacceptably high five year estimate late GI Grade 2 toxicity 26 % . Primary objective : The primary study goal ass acute toxicity Stereotactic Body Radiotherapy ( SBRT ) boost three increase dose level . Secondary objective : - Nadir PSA three month duration follow-up - Three year five year Freedom From Biochemical Failure ( FFBF ) ( Nadir + 2.0 ) - Planning feasibility ( Minor Major plan violation ) - Late Gastrointestinal Genitourinary Toxicity ( modify Radiation Therapy Oncology Group ( RTOG ) scale ) - Patient report QOL ( EPIC-SF-12 ) Hypothesis : It safe dose escalate prostate cancer treatment stereotactic boost 30Gy two fraction dominant nodule combine external beam radiotherapy 46Gy 23 fraction &lt; 15 % Grade 2 acute morbidity &lt; 5 % Grade 3 acute morbidity .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically proven prostate adenocarcinoma PSA obtain within three month prior enrollment . International Prostate Symptom Score ( IPSS ) score &lt; 15 No contraindication MRI ( pacemaker , severe claustrophobia ) Patient must able fiducial marker place prostate ( anticoagulant , must clear LMO cardiologist ) . ECOG performance status 02 Ability understand willingness sign write informed consent document . Previous pelvic radiotherapy Prior total prostatectomy Unwilling unable give inform consent Unwilling unable complete quality life questionnaire .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>Stereotactic</keyword>
	<keyword>SBRT</keyword>
	<keyword>Hypofractionation</keyword>
</DOC>